News | 24 September 2025
Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Prolia is a prescription medicine used to treat osteoporosis in women
Corning and SGD Pharma formed JV in June 2023 to expand pharmaceutical manufacturing in India
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Agency initiates safety label change and notifies physicians of possible link
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
This predictive technology empowers people with diabetes to take preventive action before complications arise
Merck opens first climate-neutral manufacturing facility in Ireland
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
The lab will facilitate the development of herbal and natural-based solutions
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
